Company profile
Phialogics AG
Our R&D platform is focused on developing immune modulating therapeutics for patients with autoimmune diseases.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". Register for more services
Partners
Contributors
